<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[PUFA metabolites (leukotrienes) drive scar tissue growth, blockade is therapeutic]]></title><description><![CDATA[<p dir="auto">Once again, PUFA rears its ugly head in health areas traditionally considered not related to fat metabolism at all. Namely, the study below shows that topical application of a lipoxygenase (LOX) inhibitor can prevent the accumulation of scar tissue. Whether LOX inhibition/blockade can completely prevent scar formation remains to be tested, but I don’t see a reason why it would not work, especially if the treatment is a combination of local (e.g. topical) and systemic (oral or IV/injection). Of course, avoidance of dietary PUFA would probably be the best approach, but since it is ubiquitous in the Western diet, LOX inhibition is probably a more practical option. Also, since scar tissue is a form of fibrosis, the study raises the possibility that other forms of fibrosis (e.g. liver, kidneys, heart, etc) would also be preventable/treatable by LOX inhibition and/or PUFA avoidance.</p>
<p dir="auto"><a href="https://es.tradingview.com/news/smallcaps:b3836b948094b:0-syntara-expands-safety-and-tolerability-study-of-snt-9465-topical-scar-treatment/" rel="nofollow ugc">https://es.tradingview.com/news/smallcaps:b3836b948094b:0-syntara-expands-safety-and-tolerability-study-of-snt-9465-topical-scar-treatment/</a></p>
<p dir="auto">“…Syntara has expanded a Phase 1b study of its next-generation topical <strong>anti-fibrotic drug candidate SNT-9465 developed to improve the structure and appearance of hypertrophic sternotomy scars</strong>.”</p>
<p dir="auto">“…Although there are differences in aetiology and location of the scars between the studies (burns vs surgical), it is anticipated that <strong>higher LOX levels may drive faster tissue turnover within the scar, creating a greater opportunity for a pan-LOX inhibitor such as SNT-9465 to remodel scar architecture</strong>. “Hypertrophic scarring remains an area of significant unmet need and we look forward to evaluating whether the biological rationale for pan-LOX inhibition translates into an acceptable safety and tolerability profile for patients,” Mr Phillips said.”</p>
<p dir="auto">Via: <a href="https://haidut.me/?p=3149" rel="nofollow ugc">https://haidut.me/?p=3149</a></p>
]]></description><link>https://bioenergetic.forum/topic/9580/pufa-metabolites-leukotrienes-drive-scar-tissue-growth-blockade-is-therapeutic</link><generator>RSS for Node</generator><lastBuildDate>Fri, 20 Nov 2026 22:56:14 GMT</lastBuildDate><atom:link href="https://bioenergetic.forum/topic/9580.rss" rel="self" type="application/rss+xml"/><pubDate>Sun, 15 Nov 2026 05:08:00 GMT</pubDate><ttl>60</ttl></channel></rss>